WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Pfizer

PfizerAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us.

www.pfizer.com

Filters
List of articles in category Pfizer
Title Published Date
Pfizer to Acquire Wyeth, Creating the World's Premier Biopharmaceutical Company 26 January 2009
Pfizer Receives FDA Complete Response Letter for Lasofoxifene 17 January 2009
U.S. Patent and Trademark Office Accepts Pfizer's Reissue Application on Lipitor 06 January 2009
Pfizer and Sigma-Tau Announce an Agreement to Market a Potential New Treatment for Malaria 10 December 2008
Pfizer's Novel HIV/AIDS Treatment SELZENTRY™ 27 November 2008
Pfizer withdraws its application to change the marketing authorisation for Viagra 20 November 2008
Pfizer Launches Global Regenerative Medicine Research Unit 14 November 2008
Pfizer and UCB Announce Formation of New Company Cyclofluidic to Accelerate Drug Discovery Process 21 October 2008
Pfizer Reaches Agreements in Principle to Resolve Litigation Involving Its NSAID Pain Medications 17 October 2008
Pfizer Launches New Medicine Safety Website for Healthcare Professionals and Patients 22 September 2008
Pfizer Will Withdraw Global Marketing Applications for Dalbavancin to Conduct a New Trial 10 September 2008
Pfizer and Medivation Enter into Global Agreement to Co-Develop and Market Dimebon 04 September 2008
IAFF Launches Smoking Cessation Campaign with Pfizer 12 August 2008
Lipitor 80 mg Reduced the Risk of Heart Attack and Stroke 07 August 2008
Pfizer Reports Second-Quarter 2008 Results 24 July 2008
Patients More Likely to Stay on Lipitor Than Simvastatin, a Large Observational Study Shows 08 July 2008
Pfizer and Ranbaxy Settle Lipitor Patent Litigation Worldwide 20 June 2008
Pfizer Celebrates 5 Years of High-Impact Corporate Volunteer Missions 16 June 2008
Pfizer Completes Acquisition of Encysive Pharmaceuticals Inc. 12 June 2008
High Dose Lipitor Can Reduce the Risk of Cardiovascular Events in Bypass Surgery Patients 22 May 2008
  • Start
  • Prev
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • Next
  • End

Business & Industry

  • GSK completes acquisition of Sierra Oncology
  • Pfizer and BioNTech announce new agreement with U.S. government to provide additional doses of COVID-19 vaccine
  • Bayer opens new Research & Innovation Center in Boston-Cambridge demonstrating its commitment to precision oncology
  • New Novartis extension phase data show nearly 80% of RMS patients treated with Kesimpta® (ofatumumab) had no evidence of disease activity (NEDA-3)
  • Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

Research & Development

  • Inhalable COVID-19 vaccine shows promise in rodent model
  • Researchers discover new leukemia-killing compounds
  • Oral antiviral drug effective against respiratory syncytial virus (RSV) identified by researchers
  • Biomarkers found that could be drug targets against a deadly form of brain cancer
  • COVID-19 rebound after taking Paxlovid likely due to insufficient drug exposure
  • Novel drug combo activates natural killer cell immunity to destroy cancer cells
  • Broadly neutralizing antibodies could provide immunity against SARS-CoV-2 variants

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Pfizer
  4. Pfizer and BioNTech announce Omicron-adapted COVID-19 vaccine candidates demonstrate high immune response against Omicron

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.